DDNews-2016 media kit.indd

2017 MEDIA KIT
2017 MEDIA KIT
ddn-news.com
ddncancer.com
Covering the News
of Pharma, Biotech
& Life Science
A global pharma readership:
From publishing our first issue in
April 2005, to celebrating our
13th year in 2017, DDNews is the only
pharmaceutical publication to evolve
from a “discovery” base to what we
are today: a full service information
resource covering the pharmaceutical
and biopharmaceutical industry from
Discovery through Clinical Trials.
Our Editorial Departments reflect
our editorial breadth and demonstrates
our functional reach:
Discovery
R&D
Preclinical
Clinical Trials
AREA OF FOCUS
Target Identification
Biomarker Discovery
■■
Lead Identification
■■
■■
Drug Development
Target Validation
■■
Lead Optimization
■■
■■
Lead Optimization
■■
ADMET
■■
Phase I
Phase II
■■
Phase III
Our major news vehicles:
Monthly Print Edition: Issued monthly to more than 39,000
global pharma professionals encompassing nearly every corner of
the globe. DDNews focuses on delivering the news of technology
and business, which keeps readers current and relevant in the
ever changing pharmaceutical industry.
DDNews Online: A twice-monthly e-newsletter that covers
breaking business stories and recent significant research findings.
DDNews website: A news portal that houses all our in-depth
content, industry resources, product literature, white papers and
archived print issues.
DDNews Cancer Research News: The only independent
website dedicated to reporting on the latest news of oncology
research, trends and resources. In addition, a special RSS feed
puts readers just one click away from up-to-the-minute
cancer-related headlines.
Global integrated marketing
opportunities to fit every budget :
MONTHLY NORTH AMERICA
PRINT EDITION
■■
■■
■■
PHA RM A,
DISCOVERY
RESEARCH & DEVELOPME
PRECLINICAL
CLINICAL TRIALS
6
NT
12
16
& LIFE SCI
ENC E
JULY 2016 : VOLUME
Answers about alp
ha-synuclein
PUBLISHE
12 : NUMBER 7
University of
Pittsburgh
team uncove
rs the
of alpha-synucle cause
in Parkinson’s in toxicity
late what we’re
doing in the laboratory
something that’s
into
going
difference for people to make a meaningful
affected by Parkinson’
disease. I believe
s
these findings
will have a
lot of impact in
the
munity. We couldn’tParkinson’s research comMedicine—for which of Pittsburgh School of
support of APDA.” have done it without the
Disease Associatio the American Parkinson
n (APDA) was
In Parkinson’s disease,
partner—has revealed
a funding
contain large clumps the failing neurons
sons why alpha-synu one of the major reaof
the
clein,
protein
a significant comsynuclein. Individual
alphaponent of the Lewy
s whose cells produce
too much of the
Parkinson’s disease, bodies that characterize
protein, or a mutated
proves
have a high risk
form,
The findings appeared toxic to neurons.
of developing Parkinson
in Science Transladisease due to alpha-synu
tional Medicine
’s
in a
clein’s toxicity.
Alpha-synuclein
binds to TOM20 paper titled “α-Synuclein
MARKET NEWS
and inhibits mitochond
protein, but much is a naturally produced
protein import
EDITORIAL/COMMENTA
3
in Parkinson’s disease.” rial
of the main culpritslike amyloid beta—one
RY
study’s lead investigato
The
PRODUCTS & SERVICES
10
r was Dr. J. Timothat, it was recently of Alzheimer’s disease
thy Greenamyre,
Love Family Professor
LATE-BREAKING NEWS
45
by the brain as an discovered, is generated
In work that
Neurology in Pitt’s
antibiotic—is not
School of Medicine of on treatmentcould have a significant impact
46
in its normal form
harmful
director of the
SPECIAL REPORT
and of researchersof Parkinson’s disease,
Pittsburgh Institute
a team
As Greenamyre and in normal amounts.
at the University
rodegenerative
tells DDNews,
Cell Biology: Sweeteni
of Pittsburgh
Diseases (PIND), for Neu- has found two ways
“We
really understand
to prevent the
who also that alpha-synu
ng the pot 20 serves as the director
Is improved understanding
[alpha-synuclein’s] do not
toxicity
of
the
clein
function;
of
APDA
glycobiology
causes.
normal
improved biologics?
Center for Parkinson’
Advanced the university’s
however,
Pictured here
the secret to
is
Cathedral of
it—by virtue of if we make too much of
Learning.
PIND and a member s Disease Research at treatment
our genetic makeup
of the APDA Scientific
s for this devastatin
PLUS:
response to environme
or in
Advisory Board.
g disease,”
Greenamyre remarked
ntal toxins—it
Special Focus on Zika
can
“It’s really exciting
in a press release. change its structural characteris
42
“I’ve been involved
that we have
tics in ways
a mechanism we
in Parkinson’s research that make it toxic. By
can target to createfound for more than 25 years,
have genetic mutationsthe same token, if we
and
new go along,
and make abnormal
the more urgency the further I forms of the
protein, it may be
I feel to transtoxic.” Though
BUSINESS & GOVERNMEN
T POLICY
TOOLS & TECHNOLOG
Y
27
32
35
BY KELSEY
KAUSTINEN
PITTSBURGH—
Some
out of the University of the latest research
37
Next-generatio
n mapping for
genomic assemblies
....................................................
Baring the bones
.................................................... .........6
MuScreen comes
.............12
on scene
On the cutting edge...............................................................35
............................................37
PITT CONTINUED
Research & Development
■■
Clinical Trials
■■
Manufacturing
■■
Regulatory
Business &
Government
2
Approval
Registration
■■
Manufacturing
■■
Regulatory Process
■■
Catalyst had
thought all that
remained for
adequate and
Firdapse to gain
well-controlled
FDA approval
study, in addition
but the company
was one
to providing
was recently
well-supported
directed to do
a follow-up study
literature,
by the FDA.
One last study in
LEMS
Catalyst inches
closer to
FDA approval
for Firdapse
BY ZACK
patients with Lambert-E
ic syndrome (LEMS), aton myasthenANCHORS
disabling autoimmu a rare, frequently
ne neuromuscular
CORAL GABLES,
disorder
announcing positive Fla.— Weeks after weaknessthat produces serious muscle
3 study of its drug results from a Phase dysfunctio and symptoms of autonomic
n.
Catalyst Pharmace candidate Firdapse,
The initial Phase
uticals is preparing
for yet another
ticenter, randomiz 3 study was a mulstudy of the drug.
ed, double-bl
follow-up research
The placebo-co
ind,
is
a
somewhat
pected hurdle that
unex- 38 patientsntrolled withdrawal trial. All
enrolled in the
the U.S. Food and emerged as a result of initially
study were
Drug Administra
treated with Firdapse
(FDA) insistence
tion’s by treatment
followed
with either
additional positive that Catalyst submit cebo
during a two-week Firdapse or plaresults from another
adequate and
randomization
period. The trial
well-controlled
was designed so
study in
that the
CATALYST
CONTINUED
ON PAGE 31
CREDIT: FDA
Contract Services
ON PAGE 9
Could microb
e
research tool iom
revolutionize
drug developm
ent?
The University of
■■
Luxembourg
‘breakthroug announces
organ-on-a-ch’ HuMiX
for the humanhip model
gastrointestinal
tract
INTEGRATED
WEBSITE
■■
■■
■■
■■
■■
BY JEFFREY
BOULEY &
RACHEL FLEHINGER
LUXEMBO URG
CITY,
Luxembou rg—
human microbiom
The
e
potential therapeuti as an area of research for
c value continues
popularity and,
to gain
in that
Luxembourg recently vein, the University of
announced the publication of a research
article
nal Nature Communica in the scientific jouron the interaction tions based on research An organ-on-a-chip model for
the human
gastrointestinal
tract could
in the gut and the between microorganisms reduce
reliance on animal do much to
development of human body through the with better
models and
the artificial Human-M
end up
results, says
the University
bial X(cross)-ta
icro- Luxembourg. Pictured
of
lk model,
here is a researcher
dealing with
HuMiX represents or HuMiX.
cell cultures.
model for the human an organ-on-a-chip in
vitro. The
gastrointestinal
and it has been
tract, expected model and resulting insights
developed to study
are
to help provide
action between
the inter- ing
a better understand
the microbiom
e, the com- omeof whether changes in the gut’s
munity of all microbial
microbicause disease, or
organisms that
in and on our body
if
such
live
changes
consequence of
are a
and the human
the disease.
host—all
HUMIX CONTINUED
■■
INTERNATIONAL
DIGITAL EDITION
ON PAGE 15
Bi-weekly
e-newsletter
Custom Content
Marketing
07.16
D SINCE 2005
CREDIT: UNIVERSITY
Diagnostics
Biomarker Discovery
■■
Assay Development
■■
Biomarker Validation
BIO TEC H
WHAT ’S INSID E
DIAGNOSTICS
CONTRACT SERVICES
■■
E-NEWSLETTERS
■■
OF PITTSBURGH
DEPARTMENT
DDNews’ circulation is focused on covering the global
pharmaceutical and biopharmaceutical industry. While some
readers are not employed by “big pharma”, these individuals work
in the expanding arena of contract research services, universities,
and government agencies like the CDC and NIH: all working on
pharma from discovery through clinical trials.
Print Circulation............................................................34,298
Digital/International Edition Circulation..................5,234
e-Newsletter Circulation.............................................82,000+
Whitepapers &
Application Notes
Research Portals
Oncology News
Online video library
Podcasts
CUSTOM
E-MARKETING
■■
Custom html
e-blasts
3
INDUSTRY
TOTAL
PERCENT
OF TOTAL
Pharmaceutical
17,799
45.0%
Biopharmaceutical
9,005
22.8%
Biotech
3,978
10.1%
Consulting firms
457
1.2%
Contract Research Manufacturing
1,068
2.7%
Government
1,151
2.9%
Clinical Research/Hospital/Medical Center
1,881
4.8%
Private Research/Independent
949
2.4%
University/College
3,099
7.8%
Other
145
0.4%
PRODUCTS USED
TOTAL
PERCENT
OF TOTAL
ADME/TOX
12,391
31.3%
Assay Development
19,388
49.0%
1.2%
Bioinformatics
18,717
47.3%
19,317
48.9%
Circulation
Demographic
Analysis
JOB TITLE
Academic Department Head/Chair
TOTAL
462
PERCENT
OF TOTAL
CEO/President/Executive
1,356
3.4%
Cellular Analysis
Consultant
361
0.9%
Cell/Tissue Culture
18,608
47.1%
7.4%
Chromatography
27,048
68.4%
14.6%
Crystallography
18,377
46.5%
19,054
48.2%
Group or Section Leader
Lab Director/Lab Mgr./Dept. Mgr.
2,944
5,769
Principal Investigator
3,914
9.9%
DNA Sequencing
Production/Process Engineer
623
1.6%
Electrophoresis
16,348
41.4%
2.6%
Epigenetics
23,326
59.0%
5.8%
Flow Cytometry
18,416
46.6%
20,038
50.7%
Professor/Instructor
Research Assistant/Grad Student/Post Doc
1,032
2,298
Research Director/VP of Research
3,209
8.1%
Fluorescence
Research Scientist
17,253
43.6%
Gene Expression
18,279
46.2%
0.8%
Genotyping
19,337
48.9%
HPLC
20,677
52.3%
18,701
47.3%
Other
311
FIELD & DISCIPLINE
TOTAL
PERCENT
OF TOTAL
HTS
Image Analysis
17,799
45.0%
Bioanalytical Chemistry
16,337
41.3%
Immunology
15,638
39.6%
Biochemistry
16,982
43.0%
Label Free Detection
16,498
41.7%
Cell Biology
16,757
42.4%
Mass Spectroscopy
26,395
66.8%
Clinical Diagnostics
14,798
37.4%
Micro Arrays
17,201
43.5%
Development/Manufacturing
13,631
34.5%
Microplate Analysis
18,677
47.2%
Genomics/Genetics
13,378
33.8%
Nucleic Acid/ Oligos
17,900
45.3%
Medicinal Organic Chemistry
16,806
42.5%
PCR
19,243
48.7%
Microbiology
14,998
37.9%
qPCR
18,602
47.1%
Molecular Biology
12,767
32.3%
Protein Expression
17,928
45.4%
Neuroscience
17,231
43.6%
Proteomics
18,016
45.6%
Oncology
13,385
33.9%
Purification
18,580
47.0%
Pharmacology
11,158
28.2%
RNAi/siRNA
18,175
46.0%
Proteomics/Protein Chemistry
7,825
19.8%
Stem Cell
24,728
62.6%
Toxicology
7,129
18.0%
Translational Research
18,598
47.0%
4
5
Circulation
Geographic
Analysis
NORTH AMERICA
TOTAL
PERCENT
OF TOTAL
Canada
428
1.1%
United States
33,759
85.4%
Mexico
111
0.3%
34,298
86.8%
CENTRAL/SOUTH AMERICA
TOTAL
PERCENT
OF TOTAL
Argentina
20
0.1%
Brazil
79
0.2%
Chile
30
0.1%
Colombia
10
0.0%
Costa Rica
2
0.0%
Ecuador
4
0.0%
Nicaragua
5
0.0%
Panama
3
0.0%
Peru
11
0.0%
Other
19
0.0%
183
0.5%
ASIA/PACIFIC
TOTAL
PERCENT
OF TOTAL
Afghanistan
3
0.0%
Australia
130
0.3%
China
181
0.5%
Hong Kong
77
0.2%
India
407
1.0%
Indonesia
21
0.1%
Malaysia
109
0.3%
EUROPE
TOTAL
PERCENT
OF TOTAL
Austria
56
0.1%
New Zealand
27
0.1%
Belgium
138
0.3%
Philippines
20
0.1%
Czech Republic
17
0.0%
Republic of Korea
257
0.7%
Denmark
71
0.2%
Singapore
111
0.3%
Finland
71
0.2%
Taiwan
55
0.1%
France
361
0.9%
Thailand
31
0.1%
Germany
380
1.0%
Other
11
0.0%
Greece
62
0.2%
1,440
3.6%
Hungary
44
0.1%
Ireland
66
0.2%
Italy
192
0.5%
AFRICA/MIDDLE EAST
TOTAL
PERCENT
OF TOTAL
Netherlands
129
0.3%
Norway
28
0.1%
Egypt
61
0.2%
Poland
29
0.1%
Iran
4
0.0%
Portugal
32
0.1%
Iraq
6
0.0%
Russian Federation
15
0.0%
Israel
41
0.1%
Spain
201
0.5%
Jordan
9
0.0%
Sweden
128
0.3%
Lebanon
2
0.0%
Switzerland
173
0.4%
Saudi Arabia
18
0.0%
Turkey
20
0.1%
South Africa
107
0.3%
United Kingdom
1,120
2.8%
Other
15
0.0%
Other
15
0.0%
263
0.7%
3,348
8.5%
39,532
100%
TOTAL
* All USA copies are print edition, all others delivered digitally.
6
7
DDNews Circulation:
Top 50 BioPharm/Biotech Companies
Rank* Company
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
Roche
Gilead Sciences
Amgen
Teva
Novo Nordisk
Actavis/Allergan
Merck KGaA
Biogen
Valeant
Celgene
Shire
CSL Behring
Grifols
Sun Pharma
UCB
Regeneron
Endo International
Alexion
Dr Reddy's
Illumina
Actelion
Novozymes
IPSEN
United Therapeutics
Jazz
Vertex
Medivation
Biomarin
Anacor
Horizon Pharma
Incyte
Alkermes
PDL Biopharma
Emergent
Acorda Therapeutics
Biocon
Amag Pharma
Seattle Genetics
The Medicines Co
China Biologic
Ionis
Aegerion
Nektar Therapeutics
Pharmamar
Genmab
Spectrum
Sciclone Pharma
Bavarian Nordic
Ariad
Morphosys
Source: HS&M Magazine
8
Print
Subscribers
e-News
Subscribers
Global
HQ Base
922
706
1,085
300
151
160
251
422
30
325
78
23
10
89
37
154
128
28
18
17
30
19
4
88
11
316
19
35
53
47
12
69
51
105
18
18
20
15
29
14
22
85
50
4
4
27
23
2
4
6
2,163
881
2,145
918
284
286
287
1,231
64
594
257
184
23
188
217
249
259
42
56
76
110
26
10
128
32
612
98
65
150
111
32
225
93
129
40
119
34
60
50
26
80
145
91
8
9
58
55
9
15
14
Switzerland
USA
USA
Israel
Denmark
USA
Germany
USA
Canada
USA
England
USA
Spain
India
Belgium
USA
Ireland
USA
India
USA
Switzerland
Denmark
France
USA
Ireland
USA
USA
USA
USA
USA
USA
Ireland
USA
USA
USA
India
USA
USA
USA
China
USA
USA
USA
Spain
USA
USA
USA
Denmark
Spain
Germany
DDNews Circulation:
Top 50 Pharma Companies
Rank* Company
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
Pfizer
Novartis
Roche
Merck & Co.
Sanofi SA
Gilead Sciences
Johnson & Johnson
GlaxoSmithKline
AstraZeneca
AbbVie
Amgen
Allergan
Teva Pharmaceutical Industries
Novo Nordisk
Eli Lilly and Co.
Bayer
Bristol-Myers Squibb
Takeda Pharmaceutical Co.
Boehringer Ingelheim
Astellas Pharma
Mylan Laboratories
Biogen Idec
Celgene
Merck KGaA
Daiichi Sankyo
Valeant
Otsuka
CSL
Baxalta
Shire
Sun
Les Laboratoires
Eisal
UCB
Abbott
Fresenius
Grifols
Chugai
CJ (CheilJedang)
Mallinckrodt
Sumitomo Dainippon
Endo
Manarini
Regeneron
Alexion
Aspen
Mitsubishi Tanabe
Nestle
Meda
Hospira
Print
Subscribers
e-News
Subscribers
Global
HQ Base
2,023
1,073
922
1,357
1,452
706
1,526
1,271
1,858
88
1,085
115
300
151
990
424
1,320
64
853
35
53
422
325
251
12
30
12
23
91
78
89
76
66
37
936
25
10
21
11
8
21
128
15
154
28
36
9
147
28
31
2,571
1,947
2,163
2,706
2,956
881
2,698
2,598
2,652
612
2,145
363
918
284
1,973
1,278
2,590
378
1,551
55
122
1,231
594
287
61
64
60
184
308
257
188
268
312
217
1921
37
23
42
24
19
38
259
33
249
42
105
28
276
60
66
USA
Switzerland
Switzerland
USA
France
USA
USA
England
England
USA
USA
USA
Israel
Denmark
USA
Germany
USA
Japan
Germany
Japan
USA
USA
USA
Germany
Japan
Canada
Japan
Australia
USA
Ireland
India
France
Japan
Belgium
USA
Germany
Spain
Japan
Korea
Ireland
Japan
Ireland
Italy
USA
USA
South Africa
Japan
Switzerland
USA
USA
Source: PharmaExec.com
9
EDITORIAL PLANNER
DATE
FOCUS FEATURE
SHOW FEATURE
January
Microbiomics
SLAS 2017
February
Cell Biology
READEX Ad Study
March
April
May
June
READEX Ad Study
September
Stem Cells
READEX Ad Study
Infectious Diseases
December
10
December 5
January 6
February 6
March 6
April 6
May 5
June 5
July 7
August 4
September 6
October 6
November 6
SHOW DISTRIBUTION
■■
■■
■■
ToxExpo
Cancer Research News
■■
■■
■■
■■
AAI
■■
American Association of
Immunology
ISSCR, ASCO
■■
■■
■■
American Society of
Clinical Oncology
CRISPR
Immuno Oncology Summit
Cancer Research News
■■
■■
■■
Sequencing/GWAS
Disease Animal Modeling
■■
■■
ASHG
■■
Neuroscience
READEX Ad Study
■■
Basel Life Science Week
SfN
October
November
MATERIALS DATE
December 1
January 3
February 1
March 1
April 3
May 1
June 1
July 3
August 1
September 1
October 2
November 1
Molecular Medicine Tri-Conference
SLAS 2017
PITTCON
ToxExpo
BioTherapeutics
AACR
Experimental Bio
AAI
PEGS
BioMarker Congress
ISSCR
ASCO
World Pharma Congress
ASMA
Cancer
July
August
SPACE CLOSING
January 2017
February 2017
March 2017
April 2017
May 2017
June 2017
July 2017
August 2017
September 2017
October 2017
November 2017
December 2017
DEPARTMENT FOCUS
AACR
Neuroscience
ISSUE DATE
■■
Cancer Research News
ASCB
Cell Biology
Cancer Research News
Next Gen Summit
Immuno Oncology Summit
Discovery On Target
BASEL Life Science Week
■■
ASHG
ELRIG
■■
Neuroscience (SfN)
■■
ASCB Cell Biology
■■
PepTalk
11
Advertising Rates
Rate card #13
NET
TABLOID PAGE
1-x
4-x
6-x
8-x
12-x
18-x
24-x
Tab Spread
$15,810
$14,750
$13,930
$13,280
$12,730
$12,340
$11,930
1/2 Tab Spread
$11,810
$11,040
$10,480
$10,020
$9,640
$9,370
$9,070
Tab Page
$8,870
$8,500
$8,030
$7,790
$7,480
$7,250
$7,040
1/2 Tab Page
$6,910
$6,510
$6,190
$5,920
$5,730
$5,570
$5,410
1/3 Tab Page
$5,360
$5,110
$4,850
$4,700
$4,500
$4,400
$4,340
STANDARD PAGE
1-x
4-x
6-x
8-x
12-x
18-x
24-x
Standard Spread
$13,450
$12,620
$12,010
$11,470
$11,040
$10,750
$10,420
Standard Page
$7,480
$6,860
$6,680
$6,410
$6,120
$5,970
$5,860
2/3 Standard Page
$6,330
$5,960
$5,680
$5,460
$5,300
$5,150
$5,020
1/2 Standard Page
$5,410
$5,090
$4,900
$4,710
$4,580
$4,440
$4,360
1/3 Standard Page
$3,400
$3,200
$3,050
$2,920
$2,820
$2,750
$2,660
1/4 Standard Page
$2,950
$2,780
$2,640
$2,550
$2,460
$2,400
$2,330
1/6 Standard Page
$2,490
$2,360
$2,250
$2,180
$2,100
$2,060
$2,020
PAGE ONE AD*
$3,120
$3,120
$3,120
$3,120
$3,120
----
----
*Page One Ad (4.75” width x 1.625” height)
TERMS AND CONDITIONS: Cancellation of any contract
requires 60 days written notice.
ALL RATES ARE NET: All rates include 4/color.
INSERTS & IMPACT PIECES
Net per
4 page insert – Standard supplied
$10,380 net
2 page insert – Standard supplied
$6,450 net
4 page insert – Standard
includes printing
$15,840 net
2 page insert – Standard
includes printing
$10,820 net
Full page cover tip on
$13,950 net
Gatefold – 6 page
$33,470 net
12
SPECIAL POSITIONS
Earned rate plus
Cover 2
15%
Cover 3
10%
Cover 4
20%
Consecutive fraction ads
15%
All other guaranteed positions
10%
TRADE SHOW FEATURE SPONSORSHIP = $18,000 net
Sponsorship includes: Two (2) Print ads (standard or tabloid)
within Trade Show Feature, sponsored by logo at top of Show
Feature section; Front Page Teaser ad – below what’s new;
Digital Edition Sponsorship with custom welcome message and
logo, and Pre-Show report eblast to 82,000+ subscribers with
exclusive leaderboard and skyscraper banner ads.
13
Production Specs
MECHANICAL SPECS
■■
■■
■■
BLEEDS
width x height (inches)
■■
Tab Page Half Tab–Horiz.
10-7/8 x 14-1/8 bleed
10-5/8 x 13-7/8 trim
10-7/8 x 7-3/16 bleed
10-5/8 x 6-15/16 trim
Half Tab–Vert.
5-1/2 x 14-1/8 bleed
5-1/4 x 13-7/8 trim
1/3 Tab–Horiz.
10-7/8 x 5-5/8 bleed
10-5/8 x 5-3/8 trim
1/3 Tab–Vert.
3-9/16 x 14-1/8 bleed
3-5/16 x 13-7/8 trim
Tab Spread
21-1/2 x 14-1/8 bleed
21-1/4 x 13-7/8 trim
Standard Page
Standard Spread
NON-BLEEDS
Tab Spread Tab Page Half Tab–Horiz. Half Tab–Vert. 1/3 Tab–Horiz. 1/3 Tab–Vert. STANDARD PAGES
Spread (non-bleed) Page (non-bleed) 2/3 Page 1/2 Page–Island 1/2 Page–Horiz. 1/2 Page–Vert. 1/3 Page–Vert. 1/3 Page–Square 1/4 Page–Vert. 1/6 Page–Vert. 14
8-3/8 x 10-7/8 bleed
8-1/8 x 10-5/8 trim
16-1/2 x 10-7/8 bleed
16-1/4 x 10-5/8 trim
width x height (inches)
20-1/4 x 12-7/8
9-5/8 x 12-7/8
9-5/8 x 6-5/16
4-5/8 x 12-1/2
9-5/8 x 4-7/8
2-13/16 x 12-7/8
width x height (inches)
15 x 10
7 x 10
4-9/16 x 10
4-9/16 x 7-1/2
7 x 4-7/8
3-3/8 x 10
2-3/16 x 10
4-9/16 x 4-7/8
3-3/8 x 4-7/8
2-3/16 x 4-7/8
■■
■■
Acceptable digital file formats: PDF or composite TIFF or EPS
files with pictures/art and fonts embedded.
Bleed ads should have 1/8-inch bleed on all sides and
crop marks should be offset by 12 pts.
All pictures should be at least 300 dpi at printed size for
CMYK and grayscale; 600 dpi for line art.
Total ink density not to exceed 260%. 110 line screen.
All color is CMYK. PMS or spot colors are not accepted.
Please send color proofs at 100%. Without a proof, DDNews
cannot be held responsible for the optimum outcome of color.
SWOP Standards apply.
E-MAIL AD MATERIALS
To [email protected] include the advertiser’s name and
issue date in the subject line.
FTP AD MATERIALS
For instructions go to www.ddn-news.com/ftp
2017 Production Schedule
ISSUE DATE
SPACE CLOSING
MATERIALS DATE
January 2017
December 1
December 5
February 2017
January 3
January 6
March 2017
February 1
February 6
April 2017
March 1
March 6
May 2017
April 3
April 6
June 2017
May 1
May 5
July 2017
June 1
June 5
August 2017
July 3
July 7
September 2017
August 1
August 4
October 2017
September 1
September 6
November 2017
October 2
October 6
December 2017
November 1
November 6
15
Website videos
3 Month Posting Electronic
Advertising
Opportunities
$2,920 flat
Feature Technology Sponsorship
3 Month Minimum $3,200 per month
An exclusive sponsorship of all related news articles specific to a
“technology” such as qPCR. Included is a 728 x 90 leaderboard,
300 x 250 big box banner, and two product releases which are
interspersed within technology editorial.
Whitepapers
3 Month Posting $1,830 net (per unit)
DDNews website ddn-news.com
Various ad sizes are available on the home page and news pages.
Ads are placed in rotation. Maximum three deep rotation.
Over 60,000 monthly visitors.
ADVERTISING RATES (net)
Ad Size
One
Month
3 months
per month
6 months
per month
12 months
per month
300 x 100
$3,070
$2,840
$2,610
$2,160
728 x 90 scrolling banner
$3,290
$3,070
$2,840
$2,390
300 x 250 Big Box
$4,080
$3,860
$3,630
$3,400
728 x 90 Leaderboard
$3,860
$3,180
$2,950
$2,610
REQUIREMENTS:
Banners must be in GIF or Animated GIF format only.
Banner size as noted above. Banners must be no larger
than 20kb in size. No transparent GIF’s or SWF accepted.
E-Mail banners to: [email protected]
16
DDNews Cancer website ddncancer.com
DDNews is the only news publication to have a dedicated
website specifically for cancer research and oncology news.
Audience is lab managers, and researchers involved in drug
discovery & development for cancer. Over 16,000 monthly visitors.
Banners
One
Month
3 months
per month
6 months
per month
12 months
per month
300 x 100
$2,300
$2,080
$1,860
$1,530
728 x 90 scrolling banner
$2,520
$2,300
$2,080
$1,860
300 x 250 Big Box
$3,280
$3,060
$2,840
$2,520
728 x 90 Leaderboard
$2,950
$2,740
$2,520
$2,300
3 Month Cancer Video Posting $2,300 (net)
E-Mail orders to: [email protected]
17
E-Newsletter
Our biweekly e-newsletter
keeps readers around
the world informed
of late breaking news,
updates, analysis, upcoming
industry events, and
commentary.
Distributed the second
and fourth Wednesday
of each month to 82,000+
qualified recipients.
Custom Content Marketing
Combining your news
and DDNews to customize
your product message.
You choose the area of
focus/subject (e.g. Cancer,
CRISPR, Immunology, etc.)
We supply five DDNews
stories to fit your subject
area; you supply two stories/
product features and
your leaderboard banner
(468 x 60). We then
mail to our 82,000+
qualified recipients, and
20,000 of your customers/
prospects (optional).
ADVERTISING RATES (net)
Ad Size
1x-5x
6x-11x
12+
300 x 100
$2,300
$2,080
$1,860
120 x 600
$3,240
$2,950
$2,740
468 x 60
$4,220
$4,010
$3,680
REQUIREMENTS:
RATE PER MAILING
CCM is available 3 times per month
$4500
Leaderboard banner must be static GIF not exceeding 20kb in size.
Banners must be in static GIF format only.
Banner size as noted above. Banners must be no larger than
20kb in size. No transparent GIF’s or SWF accepted.
E-Products & Services
Podcasts
The DDNews podcast includes:
1. Custom announcement mailing to 82,000+ qualified
DDNews recipients and a bonus mailing to 20,000 advertiser
supplied contacts (optional).
2. Advertiser receives the “read in” to the podcast,
i.e. underwriting credit within the podcast
3. Placement on DDNews website with 20 word description
and company logo.
4. It is suggested podcast be formatted as a commentary
or a Q&A session.
Podcasts content is subject to DDNews editorial approval.
Podcast will be recorded as a “Go-to-Meeting” with our
production team. Suggested length is 5 – 10 minutes maximum.
PODCAST RATES:
1 – 5x
6 – 11x
12x +
18
$4,000 net each
$3600 net each
$3200 net each
February, May,
August, November
A quarterly showcase
of new products and
services, available
with an optional
imbedded three minute
video/product
demonstration link.
Distributed by
e-mail to 82,000+
qualified recipients.
E-PRODUCTS & SERVICES (per unit)
Standard Unit Unit With Video $1,220 (net)
$1,930 (net)
Custom HTML E-mails
Get your product custom message out to the DDNews subscriber.
RATES PER MAILING
Up to 5,000 $2,910 (net)
5,000 to 6,500 $3,330 (net)
6,500 to 8,000 $3,850 (net)
8,000 to 10,000 $4,370 (net)
Mailings larger that 10,000 will be quoted
$500 net charge for split copy and/or headline per split.
19
Advertising Sales Representatives
NORTHEAST
MICHAEL STACK
1127 Kristin Drive, Suite 100, Libertyville, IL 60048
Tel: 847.922.1799
[email protected]
MIDWEST/MIDATLANTIC
RYAN KING
1900 N. Hudson, #D, Chicago, IL 60614
Tel: 773.414.9292
[email protected]
SOUTHWEST
HUTSON LAMBERT
212 E. 2nd Street, Suite 202, Pass Christian, MS 39571
Tel:228.452.9683
[email protected]
EUROPE, AFRICA, ASIA
STEPHANIE PAINTER
Painter-Lowe Communications
[email protected]
www.painter-lowe.com
Tel: +44 1634 829386
Management
BRUCE POORMAN
President & Publisher
[email protected]
LAURENCE DOYLE
Executive VP & General Manager
[email protected]
MARGE GORSLINE
Operations Manager
[email protected]
DDNews
OLD RIVER PUBLICATIONS, LLC.
19035 Old Detroit Road, Suite 203
Rocky River, OH 44116
Tel:440.331.6600
Fax:440.331.7563
www.DDN-news.com